ESSA Pharma Q2 net loss $9.0M; Phase 1 masofaniten combo shows 81% PSA90 in mCRPC

ESSA Pharma Inc.

2024-Q2 EPS reported -$0.34

Net loss $9.0M (Q2 2024) vs $7.1M (Q2 2023); R&D expense $6.2M; cash $135.9M, sufficient beyond 2025.
Phase 1 masofaniten+enzalutamide: 81% PSA90, 69% within 90 days, 63% PSA<0.2 ng/mL; median PSA progression 16.6 months.
Phase 2 enrollment completion expected Q1 2025; preliminary data mid-2025; ~25 sites active, 15 European sites by Q3 2024.
Additional arms enrolling: masofaniten+abiraterone/prednisone and +apalutamide; Phase 1b monotherapy results H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ESSA Pharma Inc. reported fiscal second quarter ended March 31, 2024 results: net income $9.0 million.

Period: fiscal second quarter ended March 31, 2024
Net income: $9.0 million
Result: reported results

Exact text from the filing

Net Loss. ESSA recorded a net loss of $9.0 million for the second quarter ended March 31, 2024 compared to $7.1 million for the second quarter ended March 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001279569-24-000603

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.